PD-1抑制剂联合来那度胺治疗复发CD5^(+)弥漫大B细胞淋巴瘤临床分析

Clinical Analysis of PD-1 Inhibitor Combined with Lenalidomide in Treatment of Relapsed CD5^(+)Diffuse Large B-Cell Lymphoma

目的:探讨复发CD5^(+)弥漫大B细胞淋巴瘤的临床特征及治疗方法。方法:收集1例CD5^(+)弥漫大B细胞淋巴瘤患者的资料,分析其临床特征、治疗转归。结果:患者合并噬血细胞综合征,经6周期R-ECHOP方案化疗达完全缓解后复发,给予PD-1抑制剂联合来那度胺治疗2周期再次达完全缓解,伴随着白介素-10表达水平下降。患者前后共化疗15个周期,病情持续处于完全缓解状态,缓解时间达24个月,白介素-10的水平持续处于正常范围。结论:PD-1抑制剂联合来那度胺方案有望成为治疗复发CD5^(+)弥漫大B细胞淋巴瘤新方案。

Objective:To investigate the clinical characteristics and treatment of relapsed CD5^(+)diffuse large B-cell lymphoma(DLBCL).Methods:The data of a patient with CD5^(+)DLBCL was collected,and its clinical characteristics and treatment outcome were analyzed.Results:The patient developed hemophagocytic syndrome and achieved complete remission(CR)after 6 cycles of R-ECHOP chemotherapy,then relapsed.After 2 cycles of PD-1 inhibitor combined with lenalidomide treatment,the patient achieved CR again accompanied by a decrease of interleukin(IL)-10 expression level.After a total of 15 cycles of chemotherapy,the patient remained in CR for 24 months,and the level of IL-10 remained in the normal range.Conclusion:PD-1 inhibitor combined with lenalidomide regimen may be a new treatment for relapsed CD5^(+)DLBCL.